Biomarker Discovery Services for Bladder Cancer
Biomarkers refer to biological indicators used to measure various physiological or pathological states. Biomarkers play a pivotal role in revolutionizing the diagnosis, prognosis, and therapy of bladder cancer. Alfa Cytology uses our advanced platform to help our clients identify new biomarkers from tissues, blood, urine, or other bodily fluids that can monitor disease progression, predict treatment response and assess toxicity.
Biomarker Development in Bladder Cancer
Bladder cancer (BC) is a complex disease with diverse molecular alterations, necessitating the identification of reliable biomarkers for non-invasive detection and drug development. Various types of biomarkers have shown promise in improving detection and monitoring of bladder cancer, including urinary tumour DNA/RNA, proteins, microbiome, long non-coding RNAs (lncRNAs), and etc. Advancements in technologies for biomarker analysis hold great promise for improving BC diagnosis and advancing personalized therapeutic strategies.
Fig.1 The biomarkers for bladder cancer (BCa) diagnosis, monitoring, and prognosis. (Zeng Y., et al. 2023)
Our Services
Alfa Cytology, a leading provider of comprehensive preclinical CRO services, offers innovative biomarker discovery services specifically tailored for bladder cancer research. The services we provide include but are not limited to:
- Biomarkers Discovery
Identification of predictive biomarkers is essential for anti-cancer drug development for bladder cancer. Using a combination of multi-omics approaches, analytical protocols for quantification and computational approaches for data processing and statistical analysis, we help drug developers generate a biomarker identification strategy to help drive the commercial success of a drug.
| Type of Target |
Type of Technology |
Type of Biomarker |
- DNA
- RNA
- Epigenetics
- Lipids
- Metabolites
- proteins
|
- Flow Cytometry
- ELISA, WB, IHC, IHF
- qPCR, FISH
- LC-MS/MS, NMR
- MRI, PET
|
- Prognostic Biomarkers
- PD Biomarkers
- Predictive Biomarkers
- PK Biomarkers
|
- Biomarker Assay Development & Validation
We provide you with fit-for-purpose biomarker validation, including RUO validation, LDT validation, clinical trial assay validation, companion diagnostic validation, and reporting to relevant organizations.
Our experience in biomarker assay development includes:
| Type of Biomarker |
Type of Matrices |
- Small molecules
- Metabolites
- Lipids
- Proteins
- Peptides
|
- DNA
- RNA
- MiRNA
- Metal Elements
- Non-Metal Elements
|
- Whole blood
- Plasma
- Serum
- Urine
- Feces
- Cells
- Tissues
|
- Biomarker Analysis
Biomarker assays and analytical readouts are important tools in drug discovery from target validation studies to candidate selection, so the ability to measure with accuracy and sensitivity is essential in making critical go/no-go study decisions. We provide our clients with reliable biomarker assay services at all stages of drug development.
Our Solutions Will Help You Achieve the Goals as Follows:
Target Expression Profiling
Mode of Action / Disease Mechanism Understanding
Biomarker Discovery / Validation
Biomarker Assay Development
PK-PD Assessment
Biomarker Analysis
Target Validation
Hit ID
Hit to Lead
Lead Optimization
Pre-IND
Clinical Development
Why Choose Us?
Professional and Well-Trained Core Technical Team.
Advanced Experimental Equipment.
Available 24 Hours a Day, 7 Days a Week.
Strict Quality Control System.
Contact Us
For researchers and organizations seeking comprehensive biomarker discovery services for bladder cancer, Alfa Cytology is the trusted partner. Whether you require biomarker identification, assay development, qualification, or analysis to meet your specific requirements, we are the preferred choice. If you are interested in our service program, feel free to contact us.
Reference
- Jeong S.H. and Ku J.H. Urinary Markers for Bladder Cancer Diagnosis and Monitoring. Front Cell Dev Biol. 2022, 2, 10: 892067.
For research use only. Not intended for any clinical use.
Related Services
